Trinity Biotech (NASDAQ:TRIB) Releases Quarterly Earnings Results, Beats Estimates By $1.16 EPS

Trinity Biotech (NASDAQ:TRIB) issued its quarterly earnings results on Tuesday. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.48) by $1.16, FiscalAI reports. The business had revenue of $9.20 million for the quarter.

Trinity Biotech Stock Performance

Shares of Trinity Biotech stock opened at $0.89 on Tuesday. Trinity Biotech has a 52-week low of $0.48 and a 52-week high of $3.44. The company’s 50 day moving average price is $0.97 and its 200-day moving average price is $2.38.

Institutional Investors Weigh In On Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Citadel Advisors LLC raised its position in Trinity Biotech PLC (NASDAQ:TRIB) by 196.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,384 shares of the company’s stock after acquiring an additional 26,084 shares during the quarter. Citadel Advisors LLC owned approximately 1.10% of Trinity Biotech worth $41,000 at the end of the most recent quarter. 78.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Trinity Biotech in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Trinity Biotech Company Profile

Trinity Biotech plc is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point‐of‐care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation.